Advertisement

Topics

Latest "Aimmune Therapeutics Inc." News Stories

06:07 EDT 23rd September 2018 | BioPortfolio

Here are the most relevant search results for "Aimmune Therapeutics Inc." found in our extensive news archives from over 250 global news sources.

More Information about Aimmune Therapeutics Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Aimmune Therapeutics Inc. for you to read. Along with our medical data and news we also list Aimmune Therapeutics Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Aimmune Therapeutics Inc. Companies for you to search.

Showing "Aimmune Therapeutics" News Articles 1–25 of 7,800+

Saturday 22nd September 2018

Sarepta Therapeutics Inc SRPT Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummarySarepta Therapeutics Inc Sarepta, is a biopharmaceutical company that focuses on the discovery and development of novel RNAbased therapeutics for the treatment of rare and neuromuscular diseases. The company develops drugs based on its proprietary, highlydifferentiated and innovative platform technology, phosphorodiamidate morpholino oligomer PMO chemistries. It principally focuses on devel...


Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries SAN DIEGO and MARLBOROUGH, Mass., Sept. 22, 2018 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral arter...

Amicus to pay US$ 100 mn to buy 10 gene therapy programmes in neurologic lysosomal storage disorders

Amicus Therapeutics announced the signing of a definitive agreement in which Amicus Therapeutics will receive worldwide development and commercial rights for ten gene therapy programmes developed


United Therapeutics ($UTHR) Acquires North American Rights to @Samumed_LLC IPF Candidate SM04646: http://ow.ly/ejp530lQNIK pic.twitter.com/12SEllgKKo

United Therapeutics ($UTHR) Acquires North American Rights to @Samumed_LLC IPF Candidate SM04646: http://ow.ly/ejp530lQNIK  pic.twitter.com/12SEllgKKo

Peritonitis Pipeline Review, H1 2018 [Report Updated: 08052018] Prices from USD $2000

Peritonitis Pipeline Review, H1 2018SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis Pipeline Review, H1 2018, provides an overview of the Peritonitis Gastrointestinal pipeline landscape.Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis SBP is the result of an infection of the...

Friday 21st September 2018

Dr. Bob Raffa Joins Bridge Therapeutics' Scientific Advisory Board Bring Decades of Research ...

BIRMINGHAM, Ala., Sept. 21, 2018 /PRNewswire/ -- Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. Read more...

Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Pla...

Amicus buys Celenex for up to $452mm, acquiring ten rare disease pipeline programs

Supporting its business strategy to move into the gene therapy arena, Amicus Therapeutics Inc. agreed to acquire privately he...

Amicus closes $150mm debt facility to fund acquisition of Celenex

Rare disease-focused Amicus Therapeutics Inc. closed a five-year senior credit facility (consisting of a $150mm term loan) wi...

Ichor's Auctus Biologics Closes Quick $1.5MM

Auctus Biologics, Inc., a new portfolio company of Ichor Therapeutics, Inc., announced today the closure of $1.5MM in seed funding. The company will develop RPtag, a hyper-stable antibody mimetic scaffold published earlier th

Big News Roundup: Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD; Ascent’s Subsidiary, Agrima Botanicals Corp., Develops Methodology for Water-Soluble Cannabinoid Delivery

In case you missed it, here is this week's big news roundup in the Life Science sector. The post Big News Roundup: Kalytera Therapeutics Provides Update for Lead Program in Prevention and Treatment of GVHD; Ascent’s Subsidiary, Agrima Botanicals Corp., Develops Methodology for Water-Soluble Cannabinoid Delivery appeared first on Investing News Network.

Remedy Plan Therapeutics Named Winner of MTC’s Inaugural Start-Up Pitch Contest at Bio+Tech18

The Maryland Tech Council (MTC) concluded its Bio+Tech18 Conference yesterday in Baltimore with the announcement of

Amicus Acquires Gene Therapy Portfolio of Ten AAV Programs in Neurologic Lysosomal Storage Disorders

CRANBURY, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced the signing of a definitive agreement in which Amicus Therapeuticswill receive worldwide development and commercial rights for ten gene therapy programs developed at The Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital and The Ohio State Universi...

St. Jude Children’s Research Hospital and Tessa Therapeutics Collaborate to Develop Novel Therapies for Brain Cancer

MEMPHIS, Tenn. and SINGAPORE, Sept. 20, 2018 /PRNewswire/ — St. Jude Children’s Research Hospital (St. Jude), the U.S. hospital leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases, together with Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the establishment of a strategic collaboration f...

Y-mAbs Upsizes IPO, Gets $96M to Test Two Pediatric Cancer Drugs

Cancer drug developer Y-mAbs Therapeutics is the latest biotech company to go public, raising $96 million in its IPO. New York-based Y-mAbs priced its offering of 6 million shares at $16 each, which was the high end of its projected range. The company had planned to sell 5.3 million shares priced at $14 to $16 […]

Celgene Drops Option to License OncoMed’s Bispecific Antibody Navicixizumab

REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Celgene has notified OncoMed that due to strategic product portfolio considerations Celgene has decided not to exercise its option to license OncoMed’s b...

Biotech Startup uBiome Raises $83M to Expand World’s Largest Human Microbiome Database

uBiome, a microbial genetics company leveraging artificial intelligence to develop wellness products, clinical tests, and therapeutics based on the microbiome, today announced it has raised $83 million in Series C funding. The round was led by OS Fund, with participation from 8VC, Y Combinator, Dentsu Ventures, and additional new and existing investors. Now, uBiome is ... Read More

Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union

LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU LUXTURNA would be first and only gene therapy approved in EU to treat patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells, a condition leading to total blindness in most patients Positive opinion based o...

Spark/Novartis eye gene therapy nears EU market – but at what price?

Spark Therapeutics’ and Novartis Luxturna gene therapy for a rare inherited eye disease has been okayed by European regulators, paving the way for an EU licence in the coming months. A marketing authorisation from the European Commission is usuall...

Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease

Novartis International AG / Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. If approved in expected timeframe, Luxturna* (voretigene neparvovec) will b...

Not The End For Exondys In EU, Says Sarepta

Sarepta Therapeutics’ hopes of marketing its controversial Duchenne muscular dystrophy drug in the EU have again been dashe...

BriaCell to Present Clinical and Scientific Data at International Cancer Immunotherapy and The MicroCap Conferences

BriaCell Therapeutics Corp. (TSXV:BCT) (OTCQB: BCTXF) ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today it will present the data from biomarker analyses of its clinical trials for advanced breast cancer at the Fourth International Cancer Immunotherapy Conference as well as at The MicroCap Conference, both of which w...

$MLNT Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) https://globenewswire.com/news-release/2018/09/21/1574256/0/en/Melinta-Therapeutics-Receives-Positive-CHMP-Opinion-for-Vabomere-meropenem-and-vaborbactam.html …

$MLNT Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam) https://globenewswire.com/news-release/2018/09/21/1574256/0/en/Melinta-Therapeutics-Receives-Positive-CHMP-Opinion-for-Vabomere-meropenem-and-vaborbactam.html …

Guided Therapeutics Announces New Agreement to Promote Sales and Marketing in Russia and Eastern Europe

Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, today announced it has signed a letter of intent with its Russian and Eastern European Sales and Marketing partner, Newmars Group Kft., to accelerate marketing and sales of the LuViva Advanced Cervical Scan in those terr...

STAT Plus: Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial. https://buff.ly/2PWqZel 

STAT Plus: Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial. https://buff.ly/2PWqZel 


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks